Supernus Pharmaceuticals (SUPN) Notes Payables (2022 - 2023)
Supernus Pharmaceuticals' (SUPN) quarterly Notes Payables came in at $402.5 million in Q1 2023, little changed on a QoQ basis from $402.0 million in Q4 2022.
Supernus Pharmaceuticals (SUPN) Notes Payables (2022 - 2023) Analysis & Trends
Supernus Pharmaceuticals (SUPN) has 2 years of Notes Payables data on file, last reported at $402.5 million in Q1 2023.
- On a quarterly basis, Notes Payables changed N/A year-over-year to $402.5 million in Q1 2023; TTM through Mar 2023 was $402.5 million, a N/A change from a year earlier, with the FY2022 full-year figure at $402.0 million, changed N/A from the prior year.
- Notes Payables for Q1 2023 stood at $402.5 million, roughly flat from $402.0 million in the prior quarter.
- Over the last five years, Notes Payables for SUPN reached as high as $402.5 million in Q1 2023 and fell as low as $402.0 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Supernus Pharmaceuticals | 2.72 Bn | 2.34 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 402.50 Mn |
| Dec 31, 2022 | 401.97 Mn |